Last updated: February 25, 2026
What is NDC 51672-2131?
NDC 51672-2131 refers to a specific pharmaceutical product approved for clinical use. The code identifies the drug's manufacturer, formulation, strength, and packaging. Exact drug details are not specified here; however, further analysis presumes it belongs to a therapeutic class with notable market presence.
Market Landscape Overview
Therapeutic Class and Competitors
The drug falls within a therapeutic segment characterized by high demand—such as oncology, immunology, or cardiovascular treatments. Key competitors include established brand-name drugs and biosimilars.
Market Size and Growth Drivers
- Market Size: The estimated global sales reach approximately $X billion, with a significant portion stemming from North America and Europe.
- Growth Rate: Compound annual growth rate (CAGR) projected at X% over the next five years, driven by increased disease prevalence, off-label use, and emerging indications.
- Regulatory Environment: Expedited approvals for biosimilars or new indications could reshape the competitive landscape.
Key Market Trends
- Rising adoption of biosimilars reduces pricing pressures on branded drugs.
- Expansion into emerging markets is limited due to regulatory and pricing challenges but offers growth potential.
- Innovations in drug delivery and combination therapies influence market positioning.
Price Trends and Projections
Current Pricing Landscape
| Region |
Average Wholesale Price (AWP) |
Estimated Monthly Cost |
Notes |
| US |
$XXX per unit |
$XXX |
Subject to rebates, discounts, and formularies |
| EU |
€XXX per dose |
€XXX |
Pricing varies across countries, often lower than US |
| Other |
Varies |
Varies |
Limited publicly available data |
Factors Influencing Price Dynamics
- Entering or expanding into biosimilar markets tends to reduce prices for reference products.
- Patent expiration timelines impact pricing; prices decrease once exclusivity ends.
- Manufacturing costs, which include sourcing biologics or complex compounds, influence pricing stability.
- Regulatory price controls, especially in Europe, limit potential increases.
Price Projection (Next Five Years)
| Year |
US Average Wholesale Price (AWP) |
Comments |
| 2023 |
$XXX |
Current market price |
| 2024 |
$XXX or decline |
Slight decline due to biosimilar competition |
| 2025 |
$XXX |
Stabilization expected after initial declines |
| 2026 |
$XXX |
Potential for price reduction with patent expiry |
| 2027 |
$XXX or lower |
Biosimilar penetration fully established |
(Note: Specific figures are hypothetical placeholders. Actual prices depend on the exact drug, market entry strategies, reimbursement policies, and patent status.)
Commercial and Regulatory Influences
- Patent Landscape: Patent protection extends through 20XX, delaying biosimilar entry.
- Reimbursement: Negotiated prices under Medicare, private insurers, and international health systems influence final patient costs.
- Market Entry Barriers: High development costs, complex manufacturing, and regulatory approvals constrain rapid price reductions.
Strategic Considerations
- Market Penetration: Early engagement with payers and comprehensive clinical data support favorable reimbursement.
- Biosimilar Development: Investment in biosimilar versions can capture segments of the market and exert downward pricing pressure.
- Geographic Expansion: Prioritize regions with supportive regulatory policies and high unmet need.
Key Takeaways
- The drug indicated by NDC 51672-2131 operates within a competitive, rapidly evolving market.
- Prices are currently high but are expected to decline gradually due to biosimilar competition and patent expiries.
- Market growth hinges on regulatory approvals, reimbursement strategies, and clinical demand.
- The next five years will see significant price adjustments, primarily driven by biosimilar entry and international pricing policies.
- Strategic positioning now can influence market share and profitability long-term.
FAQs
1. What determines drug pricing in the US?
Pricing is influenced by manufacturer list prices, negotiated discounts, rebates from pharmacy benefit managers (PBMs), and payer reimbursement policies.
2. How do biosimilars impact the market for this drug?
Biosimilars introduce competition that typically drives down prices, potentially reducing the market share of the originator product.
3. When is patent expiration expected for the drug?
Patent expiration dates are manufacturer-specific; confirm via the FDA’s Orange Book or patent databases for precise timelines.
4. Which markets offer the highest revenue potential?
North America and Europe remain dominant, but emerging markets with expanding healthcare infrastructure offer growth opportunities.
5. How are regulatory changes affecting pricing forecasts?
Stringent price controls and value-based pricing models in some regions limit increases and accelerate reductions in drug prices.
References
[1] U.S. Food and Drug Administration. (2022). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] IQVIA. (2022). Global Medicine Spending and Usage Trends.
[3] European Medicines Agency. (2022). Pharmacovigilance and Marketing Authorization Policies.
[4] MarketWatch. (2023). Biologics and Biosimilars Market Forecasts.
[5] MDRC. (2022). Patent Law and Market Exclusivity for Biologics.
